UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

 

For the Month of June 2014

 

001-36345
(Commission File Number)

 

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

8 Shaul Hamelech Blvd.

Amot Hamishpat Bldg.

Tel Aviv 6473307, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

 

Form 20-F þ Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

 

 

 

On June 12, 2014, Galmed Pharmaceuticals, Inc. (the “Company”), held a Special General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted on a proposal to elect two directors to serve as the Company’s external directors under the Israel Companies Law, 5759-1999 (the “Companies Law”) and to approve their terms of service as described in the proxy statement for the Meeting, filed by the Company with the Securities and Exchange Commission as an exhibit to the Company’s report on Form 6-K on May 7, 2014. The proposal brought before the shareholders at the Meeting has been approved by the shareholders by the requisite majority in accordance with the Companies Law.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Galmed Pharmaceuticals Ltd.
Date:  June 16, 2014	By: /s/ Allen Baharaff Allen Baharaff Chief Executive Officer